Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report)'s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.51 and traded as high as $0.71. Xtant Medical shares last traded at $0.70, with a volume of 57,296 shares traded.
Xtant Medical Stock Up 2.2%
The company has a debt-to-equity ratio of 0.42, a current ratio of 2.12 and a quick ratio of 0.88. The company has a market capitalization of $93.90 million, a PE ratio of -5.20 and a beta of 0.35. The business has a 50-day moving average of $0.53 and a 200 day moving average of $0.52.
Institutional Investors Weigh In On Xtant Medical
A hedge fund recently raised its stake in Xtant Medical stock. Renaissance Technologies LLC grew its stake in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 15.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 798,033 shares of the medical device company's stock after purchasing an additional 103,825 shares during the period. Renaissance Technologies LLC owned approximately 0.57% of Xtant Medical worth $354,000 at the end of the most recent reporting period. 69.33% of the stock is currently owned by hedge funds and other institutional investors.
About Xtant Medical
(
Get Free Report)
Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.
See Also
Before you consider Xtant Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Xtant Medical wasn't on the list.
While Xtant Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
